JP2024516645A5 - - Google Patents

Info

Publication number
JP2024516645A5
JP2024516645A5 JP2023565839A JP2023565839A JP2024516645A5 JP 2024516645 A5 JP2024516645 A5 JP 2024516645A5 JP 2023565839 A JP2023565839 A JP 2023565839A JP 2023565839 A JP2023565839 A JP 2023565839A JP 2024516645 A5 JP2024516645 A5 JP 2024516645A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
region
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026175 external-priority patent/WO2022232044A2/en
Publication of JP2024516645A publication Critical patent/JP2024516645A/ja
Publication of JP2024516645A5 publication Critical patent/JP2024516645A5/ja
Pending legal-status Critical Current

Links

JP2023565839A 2021-04-26 2022-04-25 抗clec12a抗体及びその使用 Pending JP2024516645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179755P 2021-04-26 2021-04-26
US63/179,755 2021-04-26
PCT/US2022/026175 WO2022232044A2 (en) 2021-04-26 2022-04-25 Anti-clec12a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516645A JP2024516645A (ja) 2024-04-16
JP2024516645A5 true JP2024516645A5 (https=) 2025-05-01

Family

ID=81648460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565839A Pending JP2024516645A (ja) 2021-04-26 2022-04-25 抗clec12a抗体及びその使用

Country Status (18)

Country Link
US (1) US12600784B2 (https=)
EP (1) EP4330284A2 (https=)
JP (1) JP2024516645A (https=)
KR (1) KR20240004286A (https=)
CN (1) CN117545774A (https=)
AR (1) AR125451A1 (https=)
AU (1) AU2022266584A1 (https=)
BR (1) BR112023020365A2 (https=)
CA (1) CA3216770A1 (https=)
CL (2) CL2023003177A1 (https=)
CO (1) CO2023014316A2 (https=)
EC (1) ECSP23088759A (https=)
IL (1) IL307939A (https=)
MX (1) MX2023011710A (https=)
PE (1) PE20241789A1 (https=)
PH (1) PH12023552669A1 (https=)
TW (1) TW202309084A (https=)
WO (1) WO2022232044A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
CA3212596A1 (en) 2021-04-26 2022-11-03 Michel Sadelain Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
WO2024254778A1 (en) * 2023-06-14 2024-12-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against cll1 and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DE60135352D1 (de) 2000-08-30 2008-09-25 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2010533181A (ja) 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド TNFα阻害剤の肺投与のための方法及び組成物
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション pH依存性の抗原結合を有する抗体
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
US10501545B2 (en) * 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EA202090718A1 (ru) 2017-09-14 2020-07-01 Драгонфлай Терапьютикс, Инк. Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
MX2020007338A (es) * 2018-01-09 2020-11-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
SG11202106765XA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-pd-1 binding proteins and methods of use thereof
BR112021020999A2 (pt) * 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及びclec12aに結合するタンパク質
CA3212596A1 (en) 2021-04-26 2022-11-03 Michel Sadelain Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2024518776A5 (https=)
JP2024109678A5 (https=)
JP2024516645A5 (https=)
JP2023002562A5 (https=)
JP2024504384A5 (https=)
JP2023509448A5 (https=)
JP2025067915A5 (https=)
JP2020501598A5 (https=)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2023540526A5 (https=)
JP2022533538A5 (https=)
JP2023525695A5 (https=)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2020522280A5 (https=)
JP2025508066A5 (https=)
JP2020522281A5 (https=)
JP2024540148A5 (https=)
JP2023509373A5 (https=)
JP2023510982A5 (https=)
JP2021512652A5 (https=)
JP2023542209A5 (https=)
JP2023506834A5 (https=)
JP2023524092A5 (https=)
JP2022500455A5 (https=)
JP2023552852A5 (https=)